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Abstract
Introduction: The aim of this study was to assess the analytical performances of the newly developed Access2 25-hydroxyvitamin D (25(OH)D) total 
immunoassay on two analysers, DxI800 and Access2 (Beckman Coulter, Brea, CA, USA), and compare these two and a recalibrated Modular E 170 
25(OH)D assay (Roche Diagnostics, Penzberg, Germany) with reference liquid chromatography tandem-mass spectrometry (LC-MS/MS) with special 
emphasis on clinical diagnosis.
Materials and methods: Beckman immunoassays were assessed for imprecision, accuracy, limit of blank (LoB), limit of detection (LoD), limit of 
quantitation (LoQ), linearity, interference, and carryover. One hundred and nineteen samples were run on DxI 800, Access2, and E 170, and agree-
ment with the LC-MS/MS method was evaluated.
Results: DxI 800 and Access2 assays showed good performances in terms of LoB, LoD, LoQ, linearity, and interference. All immunoassays showed 
negative biases ranging from - 8.6% (DxI 800) to - 19.2% (Access2). DxI 800 and Access2 systems had proportional biases, and the E170 system had a 
constant bias with the largest random error. Concordance correlation coefficient values ranged from 0.941 (CI: 0.917–0.958) for DxI800 to 0.854 (CI: 
0.811–0.889) for Access2. Kappa (κ) coefficients were found moderate for Dxl (0.709; CI: 0.581–0.837) and E170 (0.771; CI: 0.587–0.844) and fair for 
Access2 (0.572; CI: 0.428–0.716).
Conclusions: All immunoassays can be used in routine 25(OH)D measurements, still fairly diagnosing patients’ status. Recent standardization 
attempts seem not to contribute too much to clinical diagnosis. A clinical laboratory must at least be aware of its method to avoid misinterpretation 
of results.
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Vitamin D (VitD) deficiency results in abnormalities 
in bone metabolism such as rickets, osteomalacia, 
and osteoporosis. Moreover, it has been found to 
be related to a variety of non-bone-related condi-
tions such as cancer, diabetes, and autoimmune 
and cardiovascular diseases (1,2). This increased 
the demands for VitD testing and forced clinical 
laboratories to demand for accurate and simple 
methods suitable for routine measurements (3).
Immunoassays, liquid chromatography tandem-
mass spectrometry (LC-MS/MS), and high-perfor-
mance liquid chromatography are the analytical 
techniques currently used for 25-hydroxyvitamin 
D (25(OH)D) measurement (4). Ancient immunoas-
says had poor analytic performances in terms of 
accuracy, precision, linearity, and agreement with 
reference methods. Poor antibody specificity with 
cross-reactivity to other VitD metabolites, incom-
plete extraction of the 25(OH)D analyte from the 
vitamin D binding protein, and confounding ma-
trix substances such as lipids are proposed as po-
tential reasons for the significant differences in the 
25(OH)D determination between various assays. 
Inter-assay variations caused confusion in clinical 
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diagnosis. On the other hand, chromatography/
mass spectrometry-based assays are highly sensi-
tive and specific for measuring serum 25(OH)D 
concentrations, but the high equipment costs and 
complex measurement procedures limit its wide-
spread use. Thus, clinical laboratories largely rely 
on automated immunoassays with an improved 
accuracy and precision performance (5). To im-
prove the quality of 25(OH)D testing, identification 
of a reference method and a reference standard 
has been debated in the last decade. An interna-
tional effort to standardise the measurement of 
25(OH)D and its metabolites is currently being led 
by the Vitamin D Standardization Program (VDSP), 
which was established in November 2010 by the 
National Institutes of Health Office of Dietary Sup-
plements, Centres for Disease Control and Preven-
tion, National Institute of Standards and Technolo-
gy (NIST), and Ghent University (6). A NIST stand-
ard reference material (SRM 2972 and 972) has 
been proposed to improve the traceability and 
harmonization of 25(OH)D assays. Recently, new 
kits calibrated with reference material have been 
produced, or present ones are recalibrated to 
overcome inter-laboratory variability. The Access2 
25(OH)D assay is a competitive chemilumines-
cence enzyme immune assay, and Roche 25(OH)D 
total assay is a competitive electrochemilumines-
cence immunoassay, both presented as traceable 
to a new NIST standard. 
The hypothesis of this study was that these newly 
calibrated immunoassays minimize inter-laborato-
ry variations with an improvement in clinical deci-
sion. In this study, we aimed to assess the analyti-
cal performances of newly developed Access2 
25(OH)D assay on two analysers, Dxl 800 and Ac-
cess2 (Beckman Coulter, Brea, CA, USA), and com-
pare these two and a recalibrated Roche 25(OH)D 
(Roche Diagnostics, Penzberg, Germany) assay 
with reference LC-MS/MS and see the improve-
ment on clinical decision.
Materials and methods
Study design and subjects
This is an analytical method evaluation study; re-
cords of outpatients attending our institute on 
two consecutive days were evaluated. Adult pa-
tients (> 18 years) with no pathologic laboratory 
results and taking no medications were selected. 
A total of 124 samples out of remnant sera were 
included in the study. After LC-MS/MS measure-
ments, 4 samples having measurable 25-hydroxy-
ergocalciferol (25(OH)D2) concentrations were ex-
cluded because the number was insufficient to 
state a subgroup. One sample over the measuring 
range of E170 system was also excluded. The re-
maining 119 patient samples, with mean age of 58 
years (range 18–80 years) (54 females (45%) and 65 
males (55%)) and with different concentrations of 
25(OH)D (range 3.99–178.20 nmol/L), were evalu-
ated.
Blood sampling
Blood sampling was performed after an overnight 
fasting at 8:00–10:00 am from the antecubital vein 
into 5 ml BD Vacutainer Serum Separating Tubes II 
Advance Tube (Lot 6197520) (Becton, Dickinson 
and Company, BD Plymouth PL6 7BP, UK). Blood 
samples were centrifuged at 2000 x g for 10 min-
utes. Samples were divided in to four aliquots and 
stored at - 20 ºC for a maximum of 15 days and an-
alysed in batches on four systems. Analytical per-
formance of newly developed 25(OH)D assays was 
assessed on two platforms: UniCel Dxl 800 and Ac-
cess2. The limit of blank (LoB), limit of detection 
(LoD), limit of quantitation (LoQ), linearity, interfer-
ence, and carryover studies were performed on 
two Beckman platforms. Another 25(OH)D assay 
on E 170 (Roche Diagnostics, Penzberg, Germany) 
was included in precision, accuracy, and method 
comparisons since acceptable performance crite-
ria were based on accuracy and imprecision. Other 
analytic performance characteristics of Roche 
were supplied by the manufacturer and of LC-MS/
MS were provided from the reference laboratory.
All studies were done according to the Clinical & 
Laboratory Standards Institute (CLSI) Evaluation 
Protocols (EP) specific to each parameter. 
LC-MS/MS measurements were performed at Cen-
tro Laboratories, a certified clinical laboratory in Is-
tanbul. Three immunoassay measurements were 
performed in the biochemistry laboratory of Dr. 
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Lütfi Kırdar Kartal Research and Training Hospital 
between March and May 2016. This study was ap-
proved by the Ethical Committee of our institu-
tion.
Methods
Special applications of Access2 25(OH)D total as-
say were designed for both Dxl 800 (Cat. No. 
A98856) and Access2 (Cat. No. B24838). The total 
coefficient of variations (CV) provided by the man-
ufacturer were 9.3% for 38.94 nmol/L and 5.6% for 
399 nmol/L for Dxl 800 and 7.5% for 61.4 nmol/L 
and 6.1% for 353 nmol/L for Access2. Linearity was 
given as 4.99–524 nmol/L for Dxl 800 and 4.99–416 
nmol/L for Access2. CV values for Roche 25(OH)D 
assay (Cat. No. 05894913) provided by the manu-
facturer were 6.8% for 20.4 nmol/L and 3.7% for 
174 nmo/L. Linearity was given as 7.5–175 nmol/L. 
Both Access2 and Roche assays were claimed to 
measure both 25(OH)D2 and 25-hydroxycholecal-
ciferol (25(OH)D3) as a total and traceable to the 
NIST reference material.
LC-MS/MS reference measurements were done 
with an in-house method in Centro Laboratories, a 
certified clinical laboratory in Istanbul. The analyz-
er was Triple Quad 4500 (AB SCIEX, Framingham, 
USA). Phenomenex Kinetex 2.6 um C8 100 An LC 
column was used. It quantifies 25(OH)D3 and 
25(OH)D2 separately using atmospheric pressure 
chemical ionization and a deuterated internal 
standard. The system was calibrated with 6PLUS1 
25(OH)D3/25(OH)D2 multilevel serum calibrator (0, 
13, 39, 76, 152, 262, and 357 nmol/L) (ref. no 62039, 
Chrome systems, Munich, Germany) traceable to 
the NIST 972 reference material. The method was 
linear in the concentration range of 9.98–374.4 
nmol/L. The inter-assay CVs were 5.5% for 43.5 
nmol/L and 4.2% for 95.5 nmol/L. This laboratory 
participated in Vitamin D External Quality Assess-
ment Scheme (DEQAS). Previous five monthly ex-
ternal control results of this system showed biases 
of - 4.6%, - 0.8%, 9.4%, - 1.1%, and -2.7% from the 
target value, and peer group CVs were 10.9%, 
9.9%, 12.6%, 10.7%, and 11.1%, respectively.
Assay performance studies
Imprecision
Imprecision (within-run, between-run, and be-
tween-day) was determined using serum pools of 
two different 25(OH)D concentrations.
Imprecision (CV total) was determined using two 
serum pools at two different concentrations, low 
(32.2 nmol/L) and high (109.5 nmol/L), based on 
patient test results measured in our laboratory. Ac-
cording to the CLSI Guidelines for testing precision 
(EP5A), they were tested twice daily in duplicate, 
with a minimum of 4 hours between each run for 
20 days. Total CVs were calculated for three immu-
noassay systems.  Acceptable imprecision criteria 
was CV ≤ 10% (7).
Accuracy
Three samples provided from Randox Internation-
al Quality Assessment Scheme (RIQAS) external 
quality assessment monthly immunoassay pro-
gram (code RQ9130) were used for evaluating ac-
curacy. The first, second, and third samples of Cy-
cle 14 were analyzed once with all the methods. 
Percent difference from the published target mean 
was determined as follows: ((result – mean) / 
mean) × 100. The acceptable accuracy was defined 
as 30.2% for RIQAS.
LoB, LoD, and LoQ
Studies were done according to CLSI EP17 (8). LoB 
was determined by analyzing 20 replicates of 
manufacturer’s zero calibrator and was calculated 
using the following formula:
LoB = Mean (blank) + 1.645 SD (blank).
The limit of detection was determined using the 
lowest non-zero calibrator (14.976 nmol/L) which 
was diluted (1/2), and 20 replicates were analysed. 
LoD was calculated using the following formula:
LoD = LoB + 1.645 (SD low-concentration sample).
Limit of quantification study was performed by 
measuring samples with concentrations ranging 
from 4.822 to 38.281 nmol/L for 10 days. Six sam-
ples around the limit of quantitation indicated by 
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the manufacturer (14.976 nmol/L) were measured, 
and CVs were determined. LoQ is the point at 
which the fitted curve crosses the 20% CV line.
Linearity
Linearity was assessed according to CLSI EP6 (9). 
By diluting the highest standard of each reagent 
kit, six different concentrations in the range of 
23.5–525 nmol/L for Dxl and in the range of 17.5–
412 nmol/L for Access2 were performed and ana-
lysed for three replicates in a single run. Accepta-
ble recovery criteria were ± 15% from the target 
concentration.
Interference studies
Interference was tested for haemoglobin, biliru-
bin, and triglycerides according to CLSI EP7 A (10). 
All spiked samples were tested twice. The percent 
difference for each interferent studied was calcu-
lated using the average from the duplicate meas-
urements ((spiked – nonspiked) / nonspiked) x 
100). A deviation of more than 10% was consid-
ered significant.
For haemoglobin interference study, 6 mL of ve-
nous blood samples of healthy volunteers were 
collected to Plastic Whole Blood tubes spray-
coated with K2EDTA (BD Vacutainer, lot 367863) 
and centrifuged at 5000 x g for 5 minutes. Plasma 
was omitted, and the cell pocket at the bottom 
was washed three times with 8 mL of physiologic 
serum. Supernatant was omitted, and equal vol-
ume of distilled water was added on the erythro-
cyte pocket. The tube was placed in - 40 oC for 20 
minutes to get erythrocytes haemolysed. After 
last centrifugation hemolysate was obtained as su-
pernatant. Haemoglobin concentration was meas-
ured at LH750 haematology analyzer (Beckman 
Coulter, Brea, CA, USA). Eight different concentra-
tions of haemoglobin (range 0.25–42 g/L) was 
spiked into patient serum pools.
Bilirubin standard (≥ 98%, Sigma Aldrich B4126, 
EmM/453 = 60) was dissolved in chloroform Merck 
(M102445.2500), and different bilirubin concentra-
tions (range, 54.72–513 μmol/L) were spiked into 
serum pools for the determination of bilirubin in-
terference.
Samples prepared from the lipid standard Intralip-
id 20% (Sigma Aldrich) with four different triglycer-
ide concentrations (7.67–21.8 mmol/L) were spiked 
into serum pools for the determination of triglyc-
eride interference.
Carryover
Sample carryover was evaluated by measuring 
three replicates of a high-concentration sample 
(samples a1, a2, and a3) immediately followed by 
three replicates of a low-concentration sample 
(samples b1, b2, b3). Carryover was calculated us-
ing the equation (b1–b3) / (a3–b3), < 2% was ac-
cepted as negligible (11,12).
Method comparison
25(OH)D analyte concentrations of the samples 
within the measurement range of all systems were 
processed in a single batch, in duplicate, within 
the same freeze / thaw cycles. Method compari-
son studies were performed according to CLSI EP9 
(13).
Statistical Analysis
The distribution of data were assessed by the Kol-
mogorov–Smirnov test, and results were ex-
pressed as median and interquartile range. EP 
Evaluator Release 9 software (David G Rhoads As-
sociation, Kennett Square, PA) was used to calcu-
late imprecision, LoB, LoD, LoQ, and linearity. 
Method comparison data were evaluated using 
the Bland–Altman plots, Passing–Bablok regres-
sion, and concordance correlation coefficient 
(CCC), and kappa (κ) coefficients were done with 
MedCalc Statistical Software (version 12, Med-
CalcSoftware, Mariakerke, Belgium). Systematic er-
ror was considered significant if the 95% confi-
dence intervals did not include 1.0 for slope (pro-
portional error) or 0 for the y-intercept (constant 
error).
Diagnostic accuracy was tested with the κ coeffi-
cient. Taking 74.88 nmol/L as cut-off, patients were 
grouped as deficient and non-deficient according 
to LC-MS/MS results. Agreement of the test meth-
od in identifying patients was expressed with the 
κ coefficient. The interpretation of κ is as follows: 
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0.41–0.60 moderate; 0.61–0.80 substantial; and 
0.81–0.99 almost in perfect agreement. Kappa 
should be greater than 0.61 to be considered ac-
ceptable (14).
Results 
The assay performance studies are given in Table 
1. The median (2.5–97.5 percentiles; nmol/L) values 
of 119 samples were 50.4 (12.7–161.9) for Access2, 
56.3 (14.5–174) for DxI 800, 59.7 (7.4–163) for E170, 
and 67.8 (13.8–174) for LC-MS/MS. All three systems 
deviated negatively from reference results. Ac-
cess2 with the smallest mean had a 22.2% devia-
tion, while E170 had 11% and DxI 800 had 10% de-
viations from LC-MS/MS. Box and whisker plots 
show the distribution of results for the four meth-
ods in Figure 1.
The Bland–Altman analysis yielded negative bias-
es for all three immunoassay systems compared 
with the reference. All three biases were signifi-
cantly different from zero (P < 0.05). However, 
none of them were < 5% as VDSP suggested. DxI 
800 had the smallest bias, - 8.6%, and Access2 had 
the largest at - 19.2% (P < 0.001). The E170 system 









Low 8.9 8.1 5.2 3.9
High 8.2 7.7 2.2 1.7
Accuracy
(Deviation %)
RIQAS 1 - 23.82 - 23.49 1.46 30.12
RIQAS 2 - 1.08 - 7.13 5.88 62.82
RIQAS 3 - 16.30 0.11 7.78 29.60
LoB (nmol/L)
-
2.48 1.92 4.99† Unknown
LoD (nmol/L) 4.64 5.67 7.49† 1.60
LoQ (nmol/L) 8.61 8.84 12.48† 5.37
Linearity (nmol/L) - 23.5–525 17.5–412 7.5–175† 5.3–349
Interference
Hemoglobin (g/L) > 0.50 > 0.50 0.20† *
Triglyceride (mmol/L) > 7.67‡ > 7.67‡ > 4.52† *
Bilirubin (umol/L) > 513 > 513 > 1129† *
Carry-over % - 0.276 0.001 Not identified† -
*No interference. †Values claimed by the manufacturer. ‡Manufacturer claims were not met (Manufacturer claim was 37.06 
mmol/L ). RIQAS – Randox External Quality Assessment (EQA)/ Proficiency Testing (PT) scheme. LoB – Limit of blank. LoD – limit of 
detection. LoQ – limit of quantification.
Table 1. Performance characteristics of methods for 25(OH)D measurements
Figure 1. Box and whisker plots of 4 methods (Access2, Dxl 800, 
E170 and LC-MS/MS) for 25(OH)D measurements. 
Median values for Access2, DXL 800, E170 and LC-MS/MS were 
50.44, 56.36, 59.77 and 67.39 nmol/L, respectively, P = 0.04. Each 
box shows 25 to 75 percentile range. Horizontal line in each box 
represents group median.



















had the largest limits of agreement (- 40.1–64.5%), 
which is a measure of imprecision. Bland–Altman 
plots are shown in Figure 2.
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Figure 2. Bland-Altman plots of method comparison for 25(OH)
D measurements.
Mean (thick solid line) - percentage bias (means of paired differ-
ences). Dashed lines demonstrate the 95% limits of agreement 
(bias ± 1.96 standard deviation). Thin dotted line - line of equal-
ity.
According to the Passing–Bablok regression analy-
sis, the DxI 800 and Access2 systems had propor-
tional biases (with slope values of 0.878 and 0.748, 
respectively), while the E170 system had a con-
stant bias with an intercept value of - 2.797. This 
system had the largest random error (residual 
standard deviation, 5.10) Passing–Bablok regres-
sion analysis is shown in Figure 3.
In concordance correlation analysis, the DxI 800 
and E170 systems showed moderate agreement 
(CCC = 0.941 and 0.901, respectively).
Kappa coefficients of interrater agreement were 
found to be moderate for DxI 800 and E170 (κ = 
0.709 and 0.771, respectively) and fair (κ = 0.572) 
for Access2 systems.
Compared with Access2, the DxI 800 system 
showed a positive bias of 12.7% (P < 0.001) with an 
R value of 0.95 (intercept 2.26 [CI, 1.96–2.55], slope 
0.78 [CI, 0.74–0.82], P < 0.001) in regression analy-
sis. Method comparison data are shown in Table 2.
Discussion
Access2 25(OH)D assay showed good performance 
in LoB, LoD, LoQ, linearity, interference, and carry-
over studies on both platforms DxI 800 and Ac-
cess2. Imprecision values for both low and high 
concentrations of 25(OH)D were acceptable (< 
10%). Accuracy was found acceptable for both sys-
tems based on RIQAS criteria (30.2%). Method 
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(0.862–0.929) 0.917 0.983 - 12.2
0.77
(0.59–0.84)
CI – confidence interval. *Slope CI’s don’t include 1.0 meaning proportional error. †intercept CI’s don’t include 0 meaning constant 
error. Cb - Bias correction factor (accuracy). CCC - Concordance correlation coefficient. Ρ - Pearson correlation coefficient (precision).
Table 2. Method comparison results of immunoassays for 25(OH)D measurements with LC-MS/MS
Figure 3. Passing-Bablok regression analysis of three 
25(OH)D immunoassays compared to LC-MS/MS. The re-
gression equation is presented as  y = a + bx. a - regres-

















































50 100 150 200
Y = 0.759 + 0.880X
Y = 7.327 + 0.976X
Y = 1.644 + 0.752X
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comparison studies showed a persistent negative 
bias in all three immunoassays compared with LC-
MS/MS; the DxI 800 system had the smallest bias 
(- 8.6%), and Access2 had the greatest (- 19.2%). 
The DxI 800 and E170 systems showed moderate 
agreement (CCC = 0.941 and 0.901, respectively), 
while Access2 system was fair (CCC = 0.854). Tak-
ing 74.88 nmol/L as the cut-off for diagnostic in-
sufficiency, DxI 800 and E170 systems differentiat-
ed insufficient patients moderately (κ values 0.709 
and 0.771, respectively) as Access2 system did fair-
ly (κ = 0.572). Compared with Access2, the DxI 800 
system showed a positive bias of 12.7% (P < 0.001) 
with an R value of 0.95 (intercept 2.26 [CI, 1.96–
2.55], slope 0.78 [CI, 0.74–0.82], P < 0.001).
There were significant biases and poor CVs in 
many of the previous studies about VitD (15-17). 
Even VDSP recommendations did not contribute 
too much to assay performances and clinical diag-
nosis (18-20). In these studies, the lack of definite 
acceptable performance criteria was an important 
issue. Different CVs, biases, and accuracy goals 
were set in different studies. Enko et al. used a CV 
< 20%, referring to an opinion of the U.S. Depart-
ment of Health and Human Services, Food and 
Drug Administration (19,21). This study did not 
demonstrate a priori goal for bias. Farrell et al. used 
CV < 9.1% and bias < 15.8% as performance goals 
based on biological variation studies (16,22,23). Yu 
Chen used the DEQAS expert opinion criteria of 
CV < 22% and bias < 10% and laboratory data 
model goals of CV < 15% and bias < 10% as pro-
posed by Stockl et al. (12,24). Wyness et al. also 
used CV < 10% and bias < 15.8% as criteria based 
on the biologic variation saying that to establish a 
performance of < 5% for bias could hardly be at-
tained (25). In our study, total CV and bias values of 
all assays were acceptable according to these es-
tablished criteria in literature, but none of them 
achieved a bias of < 5%; DxI 800 could be said to 
attain a comparable one (8.61%). 
LC-MS/MS is a precise and reliable method with 
high sensitivity and specificity and is also able to 
measure 25(OH)D2 and 25(OH)D3 separately. In 
the past, LC-MS/MS methods were not in agree-
ment by themselves, and in a recent study, routine 
LC-MS/MS measurements were 11.2% higher than 
the standard reference procedure (26,27). VDSP 
also identified a standard reference procedure for 
this method and expects routine laboratory LC-
MS/MS results to be traceable to this reference 
procedure by the use of NIST reference materials. 
In our study, the results of LC-MS/MS were signifi-
cantly higher than all of the immunoassays. In ac-
curacy-based studies we held with RIQAS external 
quality assurance samples, almost all immunoas-
says gave negative biases of up to - 23.82% (except 
one bias of 0.11%). When the same samples were 
measured with LC-MS/MS, it gave positive biases 
in the range of 29.6–62.82%. Obviously, LC-MS/MS 
results were higher than immunoassays. Immuno-
assays were participants of the RIQAS, and the LC-
MS/MS system was a participant of the DEQAS 
Programme. The acceptable accuracy was defined 
as 25% for DEQAS and 30.2% for RIQAS (26). Thus, 
each method showed a comparable accuracy in its 
own program. The previous five biases obtained 
by LC-MS/MS in DEQAS were - 4.6%, - 0.8%, 9.4%, - 
1.1%, and - 2.7%, and the observed peer group CVs 
were 10.9%, 9.9%, 12.6%, 10.7%, and 11.1% respec-
tively. Regarding these data, Centro laboratory re-
sults had high accuracy, with peer group CVs 
showing the scatter of LC-MS/MS results seeming-
ly higher than expected. Though some reports 
mentioned about recently improved agreement 
among LC-MS/MS methods (28), the CV values 
above reflect the variations in DEQAS participants. 
Different from previous studies, we provided essen-
tial data describing both analytical and diagnostic 
performances of the Beckmann assays besides im-
precision and accuracy performances of the new 
Roche assay. We saw that achieving analytical 
goals did not mean better clinical diagnosis. For in-
stance, the DxI 800 system showed an acceptable 
performance in terms of imprecision, accuracy, and 
bias, and it could moderately differentiate insuffi-
cient patients (κ = 0.709) in agreement statistics. 
From the point of clinical practice, these numerical 
data mean a misdiagnosis of 33% (16/49) of non-
deficient patients as deficient. Thus, we say that 
analytical and clinical aspects of a method perfor-
mance should always be considered together.
An important limitation of this study was the lack 
of a subgroup containing VitD2. The majority of 
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supplements mostly used do not contain VitD2 in 
Turkey; thus, we could only detect measurable 
amounts of 25(OH)D2 in four patients’ sera and ex-
cluded them. Moreover, 3-epi-25(OH)D3, which 
might be present in sera of children (29), was not 
measured in this study. To avoid the influence of 
this epimer, we did not include children’s sera in 
the study.
Based on the present criteria, all immunoassays 
can be used in routine 25(OH)D measurements, 
still fairly diagnosing the patients’ status. Recent 
standardization attempts do not seem to contrib-
ute too much to clinical diagnosis. At least a clini-
cal laboratory must be aware of its method to 
avoid the misinterpretation of results.
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